Living with Parkinson's disease in Portugal: Findings from PRISM study
- PMID: 39236509
- DOI: 10.1016/j.parkreldis.2024.107124
Living with Parkinson's disease in Portugal: Findings from PRISM study
Abstract
Background: Parkinson's disease (PD) ranks second in global neurodegenerative disorders. The "Parkinson's Real-world Impact assesSMent (PRISM)" study addressed the disease burden and treatment of European PD patients. Yet, the burden on Portuguese PD patients remains unexplored. Here, we outline the demographics, clinical features, and impact of PD in the Portuguese PRISM cohort.
Methods: Descriptive analysis of the PRISM Portuguese cohort (80 patients) was performed, emphasizing socio-demographic data, anti-PD medication usage, PD impact on patients' lives and healthcare resources utilization.
Results: The predominant comorbidities in the Portuguese PD cohort (55 % male; mean age 66.2 years; mean disease duration 8.8 years) included depression (26.3 %) and anxiety (26.3 %). Levodopa was the initial prescribed anti-PD medication for 88 % of patients. Among Portuguese PDP, dopamine agonists (DA), monoamine oxidase-B (MAO-B) inhibitors, and catechol-O-methyltransferase (COMT) inhibitors were used by 50 %, 44.4 %, and 18.3 %, respectively. Portuguese PDP experienced impaired quality of life (PDQ-39 score: 31.3 ± 16.8), various non-motor symptoms, namely sadness/blues (65.4 %), urinary urgency (63.5 %), high/low sex interest (57.7 %), while 56 % reported at least one impulse control behavior. Additionally, 30.8 % retired early due to PD and 31.8 % reduced hours in daily activities. Mental health appointments were attended by 31 %, primarily in psychiatry (19 %) and psychology (6 %), and psychotherapy.
Conclusion: This study uncovers the burden of PD among Portuguese patients, revealing current treatment methods, impact on daily life and healthcare resources employed in Portugal. It emphasizes the need for personalized clinical strategies at national and international levels to improve long-term health outcomes and quality of life of PD patients.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Helena C. Brigas reports financial support and writing assistance were provided by BIAL Portela & CA SA. Ana Margarida Rodrigues reports a relationship with BIAL Portela & CA SA that includes: consulting or advisory and speaking and lecture fees. Ana Margarida Rodrigues reports a relationship with AbbVie that includes: speaking and lecture fees. Ana Margarida Rodrigues reports a relationship with Zambon S.A that includes: speaking and lecture fees. Ana Morgadinho reports a relationship with BIAL Portela & CA SA that includes: consulting or advisory and speaking and lecture fees. Ana Morgadinho reports a relationship with Zambon S.A that includes: consulting or advisory and speaking and lecture fees. Miguel F. Gago reports a relationship with BIAL Portela & CA SA that includes: consulting or advisory and speaking and lecture fees. Miguel F. Gago reports a relationship with AbbVie Inc that includes: consulting or advisory. Miguel F. Gago reports a relationship with Zambon S.A that includes: consulting or advisory and speaking and lecture fees. Rita M. Simoes reports a relationship with BIAL Portela & CA SA that includes: consulting or advisory and speaking and lecture fees. Rita M. Simoes reports a relationship with AbbVie Inc that includes: consulting or advisory and speaking and lecture fees. Rita M. Simoes reports a relationship with Stada that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous